| Methods |
Allocation: randomised, methods not specified
Masking: not mentioned
Follow up: 4 years (3 years and 1 year after cross over)
ITT analysis: |
| Participants |
N = 32 participants randomised.
Diagnosis: participants with POAG: IOP greater than 22 mmHg in both eyes (mean of the 2 highest readings of the daily phasing); glaucomatous visual field defects in at least 1 eye as assessed by a computer assisted static perimetry (Octopus G1). In case of a unilateral field defect, the fellow eye had to show optic disc cupping consistent with glaucomatous optic neuropathy
Exclusion criteria: previous antiglaucoma treatment, smoking, history of allergic and respiratory disease, including asthma and atopy assessed by skin prick testing.
Participants who experienced IOP > or = 22 mmHg during follow up were excluded
Age: 44 to 67 years
Gender: 17 women and 15 men
History: not mentioned |
| Interventions |
1. ALT (n = 16)
2.0.5% timolol twice daily (n = 16)
No other treatment was administered to these participants during the follow up. If the IOP reached 22 mmHg or more the participant was excluded |
| Outcomes |
Primary: change in the PC20, the provocative concentration that reduced at least 20% of the forced expirated volume, presented in a logarithmic transformed value |
| Notes |
|
| Risk of bias |
| Bias |
Authors' judgement |
Support for judgement |
| Allocation concealment? |
Unclear risk |
B ‐ Unclear |
